
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Filters
Status
Categories
- Remove Advertising filter Advertising (2)
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Remove Biologicals filter Biologicals (2)
- Complementary medicines (7) Apply Complementary medicines filter
- Fees/Payments (1) Apply Fees/Payments filter
- Remove Import/Export filter Import/Export (1)
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Remove Legislation filter Legislation (3)
- Remove Listed medicines filter Listed medicines (2)
- Manufacturing (1) Apply Manufacturing filter
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Medical devices safety (1) Apply Medical devices safety filter
- Medicinal cannabis (1) Apply Medicinal cannabis filter
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- OTC medicines (12) Apply OTC medicines filter
- Other therapeutic goods (1) Apply Other therapeutic goods filter
- Prescription medicines (6) Apply Prescription medicines filter
- Scheduling (55) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Remove Therapeutic goods regulation filter Therapeutic goods regulation (2)
- (-) Remove Import/Export filter Import/Export
- (-) Remove Listed medicines filter Listed medicines
- (-) Remove Biologicals filter Biologicals
- (-) Remove Legislation filter Legislation
- (-) Remove Therapeutic goods regulation filter Therapeutic goods regulation
- (-) Remove Advertising filter Advertising
Priority Review pathway for biologicals: feasibility, potential eligibility criteria and determination process
Closed on 28 March 2022
Consultation on potential regulatory options for 'export only' biologicals
Closed on 20 December 2021
Proposed changes to the Permissible Ingredients Determination: Low-negligible risk changes 2021-22
Closed on 15 September 2021
Remaking of standards and legislative instruments for human cell and tissue (HCT) products, blood and blood components
Closed on 11 July 2021
Proposed improvements to the Therapeutic Goods Advertising Code
Closed on 18 June 2021
Standard for vaporiser nicotine (TGO 110)
Closed on 31 March 2021
Export of therapeutic goods from Australia
Closed on 3 February 2020
Changes to permissible ingredients - Low-negligible risk
Closed on 11 October 2019
Proposed clarification that goods are therapeutic goods - goods containing folate substances in certain circumstances
Closed on 18 September 2019
Options for the future regulation of 'low risk' products
Closed on 12 May 2017